Abstract Between March 2003 and March 2009, five breast cancer patients with single or multiple but localized liver metastases were treated with proton beam therapy (PBT). A total dose of 66 GyE in 10 fractions or 72.6 GyE in 22 fractions was delivered, depending on tumor location. Systemic therapy was administered for more than 1 year before and after PBT. All irradiated tumors were wellcontrolled until last follow-up (median 33.3 months), but recurrence at other sites was observed for all patients: two patients had intrahepatic recurrence only, one patient had both intrahepatic and extrahepatic recurrence, and two patients had extrahepatic recurrence only. The median time from PBT to first recurrence was 10.8 months. PBT-related toxicity of grade 3 or greater was not observed, and additional PBT was successfully given to two patients who had single intrahepatic recurrence after initial PBT. The results indicate the usefulness of PBT for single or multiple, but localized, liver metastases in patients whose hepatic metastatic tumors are unsuitable for surgical resection or radiofrequency ablation.
Introduction
Systemic hormonal therapy and/or chemotherapy are regarded as standard treatment methods for patients with distant metastasis from primary breast cancer. However, median survival time (MST) is only 12-24 months when systemic therapy is given alone [1, 2] . In recent studies in which systemic therapy was combined with hepatic resection, 5-year survival of patients with liver metastasis was 21-61 %, with MSTs ranging from 27 to 63 months [3] [4] [5] [6] [7] [8] , indicating that surgical resection improves the survival of these patients.
Because of its unique physical characteristics, proton beam therapy (PBT) can minimize toxicity to normal tissue while resulting in better dose distribution to the target than photon therapy. Therefore, PBT has been used for treatment of hepatocellular carcinoma (HCC) with cirrhosis; some reports showed good local control with acceptable toxicity [9] [10] [11] [12] [13] [14] . In our experience, 5-year local control after PBT for HCC was 81 % [9] . Hence, PBT may be an alternative treatment to hepatic resection for patients with liver metastasis. In this report, we describe our initial experience and treatment outcomes for PBT for liver metastasis primarily from breast cancer.
Case report

Clinical presentation
Between March 2003 and March 2009, five women with liver metastasis primarily from breast cancer were treated with PBT at our hospital. Characteristics of the patients are summarized in Table 1 . The median age was 46 years, and initial Eastern Cooperative Oncology Group performance
Proton Medical Research Center and Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan e-mail: ayaek@pmrc.tsukuba.ac.jp status was either 0 or 1. Single or multiple, but localized, liver metastases without any extrahepatic distant metastases were found in all patients. The median size of liver metastatic tumors was 40 mm. Four tumors were progressive and the remaining tumor was persistent in size at initiation of PBT, although systemic therapy had already been administered for more than 1 year.
Proton therapy
All patients received PBT; systemic hormonal therapy and/or chemotherapy was given adjuvantly. The total dose delivered was 66 cobalt-Gray-equivalent (GyE) in 10 fractions or 72.6 GyE in 22 fractions; this was used for HCC on the basis of a linear quadratic model assuming a/b = 10 for the tumor [9] [10] [11] [12] . Considering the possibility of late complications in organs at risk, for example bile duct stricture and gastrointestinal ulceration, dose fractionation of 72.6 GyE in 22 fractions was selected when the tumor was located adjacent to the porta hepatis and near the intestinal tract. Consequently, three patients received PBT at a total dose of 66 GyE in 10 fractions, and two patients received a total dose of 72.6 GyE in 22 fractions. The relative biological effectiveness of proton beams was assumed to be 1.1 [15] . The clinical target volume encompassed the gross tumor volume with a 5 to 10-mm margin in all directions [9] . Proton beams were delivered during the expiratory phase under a respiration-gated system [16] , but an additional 5-mm margin was included on the caudal axes to compensate for uncertainty because of respiration-induced hepatic movements.
The median follow-up time was 33.3 months (range 20.3-102.4 months). Complete response and partial response of the irradiated liver tumors were achieved in two and three cases, respectively (Table 1 ; Fig. 1 ). PBT-related toxicity of grade 3 or greater was not observed and no liver dysfunction was found (Table 2 ) when acute and late treatment-related complications were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (v.3.0). After PBT, there was no recurrence within the irradiated volumes, but all patients had recurrence outside the irradiated area: two patients had only intrahepatic recurrence, one patient had both intrahepatic and extrahepatic recurrence, and two patients had only extrahepatic recurrence (Table 3 ). The median interval from liver irradiation to first recurrence was 10.8 months (range 2.9-26.5 months). Two patients with a single liver metastasis (cases 1 and 2) were treated with PBT again.
Clinical outcome for patients is summarized in Table 4 . MSTs from initial diagnosis of breast cancer and from diagnosis of the first liver metastasis were 95.1 months (range 40.1-200.7 months) and 67.1 months (range 40.1-148.1 months), respectively. All patients were still alive with (n = 2) or without (n = 3) recurrent tumors at last follow-up. One patient with multiple lymph node and bone metastases had mild numbness in her feet because of bone metastases, but the other patients had no symptoms of the disease.
Discussion
Patients with distant metastases from breast cancer are usually treated with systemic hormonal therapy and/or chemotherapy; 50-80 % of patients respond to this therapy, which may help increase their survival [5] . Previous studies reported that MSTs of patients with distant metastases after systemic therapy alone were 12-24 months [1, 2] . The liver is one of most common sites of metastases from primary breast cancer, and an isolated liver metastatic tumor appears in 3-5 % of patients after curative surgery [2, 17] . MSTs and 5-year survival after hepatic resection combined with systemic therapy were 27-63 months and 21-61 %, respectively [3] [4] [5] [6] [7] [8] . Therefore, hepatic resection is effective therapy for medically and technically operable liver metastasis. In contrast, MSTs of breast cancer patients with liver metastases were 5-31 months when standard systemic therapy alone was given [18] . Recent reports on radiofrequency ablation or transcatheter arterial chemoembolization with systemic therapy for patients with liver metastases also revealed that MSTs were 15-32.5 months [18] [19] [20] . Therefore, intensive but non-invasive local therapy for medically or technically unresectable liver metastasis should be standardized.
Modern highly conformal radiotherapy techniques enable us to treat cancer patients with better tumor control and less toxicity to normal tissues than for previous conventional methods. Specifically, it is possible to safely treat small hepatic lesions with high doses of radiation by use of stereotactic techniques, because the liver is regarded as a parallel organ according to radiobiology [21] . Previously, an extremely large single dose of 20-30 Gy using a stereotactic body radiation therapy (SBRT) technique was attempted [22] . A total dose of 36-60 Gy in 3 fractions has led to promising results, achieving local control for 90 % of tumors with low incidence of complications [23] [24] [25] .
The optimum irradiation dose and fractionation for liver metastasis is still unclear, but an apparent dose-response relationship has been described for patients undergoing SBRT for liver metastases. On the basis of the estimation model of biological effective dose (BED), the range of values for BEDs in three-fraction SBRT studies was between 66 Gy 10 and 150 Gy 10 in equivalent dose with a conventional fraction dose of 2 Gy. The normalized total dose with a fractional dose of 2 Gy in the cases of this analysis ranged from 81 to 91 Gy 10 E, which is almost equal to those in the SBRT series. The dose fractionations of 66 GyE in 10 fractions and 72.6 GyE in 22 fractions, which are used in the PBT procedure for treatment of HCC [9] [10] [11] [12] , are also effective for liver metastasis from breast cancer. Fortunately, there was no recurrence at areas irradiated by PBT at the last follow-up (median follow up time: 33 months). Achieving local cure of liver metastases without causing liver dysfunction is an attractive treatment objective for patients with localized liver metastases. Because of the physical advantages of PBT, three-dimensional dose concentration to liver tumors with 2-3 portals using proton beams is much safer than that with 6-10 portals or rotation-arcs given by SBRT in terms of sparing the normal liver tissue from high doses of irradiation. In fact, PBT-related liver toxicity of grade 2 or greater was not observed in this case analysis.
In terms of out-field hepatic recurrence, reported recurrence ranged from 15.8 to 58.3 % [4, 19] even when systemic therapy was combined with locally aggressive treatment for apparently visible metastatic lesions. The time between treatment for liver metastasis and further recurrence is 15-36.1 months [4, 5] . Some reports have shown that initial extrahepatic recurrence after treatment for liver metastasis occurred in 12.5-25 % of patients [4, 19] mean time of 22 months [4, 5] . In this case analysis, out-field recurrence was also observed for all patients. However, two patients were treated with PBT asynchronously, and had no recurrence and no liver dysfunction at last follow-up. Because the area irradiated by protons is much smaller than that by photons at a prescribed dose, PBT seems better for re-irradiating the second liver metastasis without irradiating non-target liver tissue.
in a
In conclusion, this case analysis showed that hypofractionated high-dose PBT might be a non-invasive but intensive local treatment method which achieves local control of liver metastasis from primary breast cancer with minimum morbidity. On the basis of these results we have also started to treat patients with limited liver metastases from colon cancer. However, because out-field recurrence was often observed after PBT and after other local treatment, appropriate systemic therapy had to be considered to improve the patient's survival. It seems that PBT is a safe and effective treatment for patients with single or multiple, but localized, liver metastases from breast cancer. 
